SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is under pressure as traders react to the boards investigation into CEO Jensen Huangs admitted affair and allegations that the woman involved had ties to Chinese intelligence; the espionage claims remain unverified. The community is split between concerns about leadership and disclosure risks and views that the selloff is an overreaction and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is drawing attention ahead of its quarterly results after a sharp share-price decline, with traders debating whether the selloff signals weak results or is an opportunity to buy the dip. The Eli Lilly obesity-drug partnership is viewed as a growth opportunity, but some investors worry that branded medications could pressure margins; speculation about an earnings leak remains unverified.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors HOPE-3 cardiac results receiving an American Heart Association research award has renewed attention to deramiocel ahead of the FDAs November 22 PDUFA decision for Duchenne muscular dystrophy. Traders are largely hopeful for approvalespecially on upper-limb function, which they distinguish from the advisory panels negative cardiac votewhile others stress that the outcome and any cardiac label remain uncertain.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC findings on immune activation and viral clearance, alongside its positive Phase 3 prostate-cancer results, are drawing attention as the company prepares a BLA for CAN-2409. Bulls see the data as supportive of the regulatory package, while skeptics question filing and manufacturing execution and warn of a possible sell-the-news reaction.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing support from Oppenheimers upgrade to Outperform on its AI and data-center outlook, alongside community discussion of Google Cloud using EPYC processors in its TPU infrastructure. Traders also see a possible rotation from Nvidia amid headlines about a board investigation into CEO Jensen Huang, while some caution that AMDs valuation and the sharp run-up leave room for volatility.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are surging ahead of its Q3 results, with traders speculating about short covering and an possible earnings leak, though neither is confirmed. Bulls hope for a turnaround and stronger guidance, while skeptics warn that slowing ad growth and past post-earnings declines could lead to a reversal.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is drawing attention as traders debate whether renewed scrutiny around Nvidia CEO Jensen Huang and alleged China-related chip diversions is weighing on the stock by association; some argue the concerns are speculative or unrelated to SMCI. The debate is sharpened by the stocks weak performance despite recent strong results and raised guidance, with bulls pointing to its valuation and bears citing governance, cash flow, and margin risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of +30.00% and +19.08%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

BridgeBio Reports Lower Clinical Event Risk With Acoramidis Vs Tafamidis In Heart Amyloidosis

(RTTNews) - BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM...

BridgeBio Pharma Becomes Oversold (BBIO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis DayPR NewswirePALO ALTO, Calif., Oct. 6, 2026October 6 YouTube premiere featuring Sway...

Top Analyst Reports for ExxonMobil, Automatic Data Processing & Cadence

ExxonMobil, ADP and Cadence highlight today's analyst reports, with growth drivers, market risks and strategic moves shaping their outlooks.

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• Reported GAAP EPS of -$0.42 up 55.79% YoY
• Reported revenue of $353.17M up 192.60% YoY

BridgeBio's Q3 2026 operating costs and expenses increased to $364.8M, nine-month operating cash use was $312.6M, and regulators may disagree with approval strategies or submitted data.

BridgeBio reported Attruby revenue growth and increased treatment-nave starts; real-world studies reported lower clinical worsening with acoramidis versus tafamidis, while three priority-review decisions fall within the next seven months.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB inked deals with the Trump administration on Monday.&nbsp;</li><li>The nine companies pledged at least $19.6 billion in near-term U.S. factory spending.</li><li>U.S.-listed shares tied to the White House’s latest drug-pricing deals were quiet after the closing bell Monday, with no sharp move.</li></ul>President Donald Trump on Monday said nine mid-sized drugmakers have agreed to lower drug prices in the U.S., including Alcon (ALC), Astellas, BeOne Medicines (ONC), BridgeBio (BBIO), CSL, Kyowa Kirin, Sun Pharma, Teva (TEVA), and UCB.Under the deals, they would charge Americans no more than the lowest price paid in other rich countries, similar to big-pharma companies that inked similar deals with the Trump Administration last year. The medicines treat conditions such as cancer, Parkinson’s, hemophilia, eye disease, liver disease, and skin problems. The same rule would also apply to new drugs launched by these companies later.The nine companies pledged at least $19.6 billion in near-term U.S. factory spending. Some also said they will donate drug ingredients to a U.S. emergency reserve.U.S.-listed shares tied to the White House’s latest drug-pricing deals were quiet after the closing bell Monday, with no sharp move. Teva Pharmaceutical closed down 1.1%, then gained 2% in after-hours trading. BeOne Medicines finished down about 2%, and held that level after the close. BridgeBio was essentially flat in the regular session and ticked slightly higher after hours. Alcon shares were little changed.<h2 class="st-heading-2">Trump’s Pricing Push</h2>The fresh deals follow a push that began in 2025. Trump signed an order seeking “most-favored-nation” prices, then sent letters to 17 of the world’s largest drugmakers. He warned of tariffs on imports if they did not cut U.S. prices.Pfizer went first in September 2025. AstraZeneca and EMD Serono followed. In November, Eli Lilly and Novo Nordisk agreed to steep cuts on popular weight-loss and diabetes shots sold through TrumpRx.gov and at $50 a month for many Medicare patients.In December, nine more giants signed on in one day: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. Johnson &amp; Johnson and AbbVie followed in January. Regeneron was the last among the companies targeted by Trump to ink a most-favored-nation deal, after signing in April. Those earlier pacts mixed lower Medicaid prices, cash discounts on a government website, factory spending in the United States, and relief from drug tariffs.The White House said on Monday that earlier deals plus the fresh nine now cover 26 companies and 89% of the branded drug market. Every state Medicaid program would get those lower prices. Officials said that would save billions. The president’s economic team estimates all of the deals will save $600 billion over 10 years.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TEVA was bullish. Sentiment around BBIO and ONC, however, was neutral while ALC was bearish.Among those who inked deals with the administration on Monday, <a href="https://stocktwits.com/symbol/TEVA">TEVA</a> gained 16% year-to-date and <a href="https://stocktwits.com/symbol/ONC">ONC</a> 18%. ALC has fallen 9% year-to-date, while <a href="https://stocktwits.com/symbol/BBIO">BBIO</a> traded flat. 'Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-jumps-as-cybercabs-hit-texas-robotaxi-roster-ahead-of-launch-event/cZYz5JWRJsy">TSLA Stock Jumps as Cybercabs Hit Texas Robotaxi Roster Ahead Of Launch Event</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Brandon Wiley, Pharm D., pharmacist at Wiley Pharmacy in Lancaster, works at Wiley Pharmacy. Photo by Susan L. Angstadt 1/28/2015 (Photo By Susan L. Angstadt/MediaNews Group/Reading Eagle via Getty Images)

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries. 

Alcon Inc. - Registered Shares

BeOne Medicines Ltd - ADR

Teva- Pharmaceutical Industries Ltd. - ADR

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Current Price	$77.53
Prev Close	$74.29
Open	$74.72
Dividend Yield	0.00%
50-Day Moving Average	$69.76
Beta	1.16
Avg. Volume	2.83M
PE Ratio	-24.44

52-Week High	$93.42
52-Week Low	$62.06
Market Capitalization	$14.47B
EPS (Annual)	-$3.79
Price to Book	-5.59
Revenue Per Employee	$598,421.93

Feed

News

Sentiment

Earnings

Fundamentals

Info

BBIO Fundamentals